A high proportion of germline variants in pediatric chronic myeloid leukemia

• Published in: Molecular cancer 2024-09, Vol.23 (1), p.206-9, Article 206
• Main Authors: Krumbholz, Manuela, Dolnik, Anna, Sträng, Eric, Ghete, Tabita, Skambraks, Sabrina, Hutter, Stephan, Simonis, Alfred, Stegelmann, Frank, Suttorp, Meinolf, Horn, Anselm H C, Sticht, Heinrich, Haferlach, Torsten, Bullinger, Lars, Metzler, Markus
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Cancer predisposition; Child; Child, Preschool; Children; Chronic myeloid leukemia; Correspondence; Development and progression; Exome Sequencing; Female; Fusion Proteins, bcr-abl - genetics; Genes; Genetic Predisposition to Disease; Germ-Line Mutation; Germline variants; Health aspects; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Male; Pediatric CML; Pediatrics
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-024-02109-5

Chronic myeloid leukemia (CML) typically occurs in late adulthood. Pediatric CML is a rare form of leukemia. In all age groups, the characteristic genetic driver of the disease is the BCR::ABL1 fusion gene. However, additional genomic events contribute to leukemic transformation, which is not yet well-characterized in pediatric CML. We investigated the mutational landscape of pediatric CML to determine whether predisposing germline variants may play a role in early-age disease development. Whole exome sequencing and targeted sequencing were performed in pediatric and adult CML samples to identify age-related germline and somatic variants in addition to the BCR::ABL1 translocation. Germline variants were detected in about 60% of pediatric patients with CML, with predominantly hematopoietic genes affected, most frequently ASXL1, NOTCH1, KDM6B, and TET2. The number of germline variants was significantly lower in adult patients with CML. If only confirmed pathogenic variants were regarded as cancer-predisposing variants, the occurrence was ~ 10% of pediatric CML, which is comparable to other hematological malignancies and most childhood cancer entities in general. We hypothesize that the interaction with the strong oncogene BCR::ABL1 may also favor the development of leukemia by weaker variants in the same genes. In pediatric patients, the germline variants of genes associated with clonal hematopoiesis may increase the likelihood that an incidental BCR::ABL1 translocation triggers the early manifestation of CML.